ArticlePloS one2019
The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation.Health technology assessment (Winchester, England) · 2024Pooled it
- Impact of first-trimester preeclampsia screening on perinatal and maternal morbidity: the RANSPRE open multicenter randomized trial.BMC pregnancy and childbirth · 2026Trial
- Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more.PLoS neglected tropical diseases · 2024Trial
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Treatment of congenital toxoplasmosis with pyrimethamine combined with sulfadiazine in a Chinese neonate: a case report.Frontiers in pediatrics · 2026Article
- Estimating the national seroprevalence ofEpidemiology and infection · 2025Article
- Routine antenatal toxoplasmosis screening, is it necessary?Turkish journal of obstetrics and gynecology · 2025Article
- Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025Article
- Impact of Experimental Congenital Toxoplasmosis on the Thyroid Gland: Histopathological and Immunobiochemical Indices Assessment.Acta parasitologica · 2025Article
- Gestational toxoplasmosis treatment changes the child's prognosis: A cohort study in southern Brazil.PLoS neglected tropical diseases · 2023Article
- TORCH Congenital Syndrome Infections in Central America's Northern Triangle.Microorganisms · 2023Article
- Seroepidemiology of toxoplasmosis in pregnant women and detection of infection acquired during pregnancy in Cotonou, Benin.Parasite (Paris, France) · 2023Article
- Long-Term Outcomes in Children with Congenital Toxoplasmosis-A Systematic Review.Pathogens (Basel, Switzerland) · 2022Review
- Congenital toxoplasmosis: Should we still care about screening?Food and waterborne parasitology · 2022Article
- Efficiency of a Single well IgG, IgM and IgA Anti T. gondii Fluorimetric Assay for Pre-natal Screening for Congenital Toxoplasmosis.Journal of fluorescence · 2022Article
- Prevention of congenital toxoplasmosis in France using prenatal screening: A decision-analytic economic model.PloS one · 2022Article
- Congenital Toxoplasmosis: The State of the Art.Frontiers in pediatrics · 2022Review
- Retrospective study of toxoplasmosis prevalence in pregnant women in Benin and its relation with malaria.PloS one · 2022Article
- Association between lymphadenopathy after toxoplasmosis seroconversion in pregnancy and risk of congenital infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- High performance of a novel point-of-care blood test forEmerging microbes & infections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments.
methodTo identify cost-effective strategies, prenatal and neonatal screenings were compared using a decision-analytic model based on French guidelines and current knowledge of long-term evolution of the disease in treated children. Epidemiological data were extracted from the scientific literature and clinical data from the French Lyon cohort. Strategies were compared at one year of age, when infection can be definitively evaluated, and at 15 years of age, after which validated outcome data become scarce. The analysis was performed from the French Health Insurance System perspective and included direct medical costs for pregnant women and their children.
resultsThe 1-year Incremental Cost-Effectiveness Ratio showed that prenatal screening would require investing €14,826 to avoid one adverse event (liveborn with CT, fetal loss, neonatal death or pregnancy termination) compared to neonatal screening. Extra investment increased up to €21,472 when considering the 15-year endpoint.
conclusionsPrenatal screening is cost-effective as compared to neonatal screening in moderate prevalence areas with predominant Type II strains. In addition, prenatal screening, by providing closer follow-up of women at risk increases the number of occasions for education avoiding toxoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.